Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics

Author： Sehrt Daniel   Meineke Ingolf   Tzvetkov Mladen   Güültepe Senol   Brockmööller Jüürgen  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.12, Iss.6, 2011-06, pp. : 783-795

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacogenetics and Drug Therapy in Psychiatry - The Role of the CYP2D6 Polymorphism

By  

Current Pharmaceutical Design, Vol. 13, Iss. 2, 2007-01 ,pp. : 241-250

Bentham Science Publishers

Access to resources Recommend Favorite

Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers

By Pedersen Rasmus Steen   Damkier Per   Brøsen Kim  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 513-521

Springer Publishing Company

Access to resources Recommend Favorite

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol

By  

Current Drug Metabolism, Vol. 17, Iss. 1, 2016-01 ,pp. : 30-36

Bentham Science Publishers

Access to resources Recommend Favorite

Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

By Kirchheiner J.  

Clinical Pharmacokinetics, Vol. 43, Iss. 4, 2004-01 ,pp. : 267-278

Adis International

Access to resources Recommend Favorite

The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype

By Al-Shurbaji Ayman   Säwe Juliette  

European Journal of Clinical Pharmacology, Vol. 57, Iss. 12, 2002-02 ,pp. : 877-881

Springer Publishing Company

Access to resources Recommend Favorite